New antiepileptic drugs in pediatric epilepsy

Brain and Development

Volumn 30, Issue 9, 2008, Pages 549-555

  Hwang, Hee ^a   Kim, Ki Joong ^a  

^a Seoul National University Children's Hospital   (South Korea)

Author keywords

Antiepileptic drug; Evidence based; Pediatric epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; ADD ON THERAPY; ADJUVANT THERAPY; ADOLESCENT; AGGRESSION; ANHIDROSIS; ANOREXIA; ANTICONVULSANT THERAPY; APLASTIC ANEMIA; ASTHENIA; ATAXIA; BEHAVIOR CHANGE; CHILD; CHILDHOOD DISEASE; CHOREOATHETOSIS; CLINICAL PRACTICE; COGNITIVE DEFECT; COMPLEX PARTIAL SEIZURE; CROSS ALLERGY; DECREASED APPETITE; DEPERSONALIZATION; DIPLOPIA; DIZZINESS; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EVIDENCE BASED PRACTICE; FATIGUE; FOCAL EPILEPSY; FOOD AND DRUG ADMINISTRATION; GAIT DISORDER; GENERALIZED EPILEPSY; HEADACHE; HOSTILITY; HUMAN; HYPERACTIVITY; HYPERTHERMIA; HYPONATREMIA; INFANT; INFANTILE SPASM; INFECTION; INSOMNIA; LANDAU KLEFFNER SYNDROME; LENNOX GASTAUT SYNDROME; LEUKOPENIA; LIVER TOXICITY; MENTAL INSTABILITY; METABOLIC ACIDOSIS; MONOTHERAPY; MYOCLONUS EPILEPSY; NAUSEA; NEPHROLITHIASIS; NONHUMAN; NYSTAGMUS; PARESTHESIA; PEDIATRICIAN; PHYSICIAN; PRACTICE GUIDELINE; PRURITUS; PSYCHOSIS; RASH; RECOMMENDED DRUG DOSE; RETT SYNDROME; REVIEW; ROLANDIC EPILEPSY; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TONIC CLONIC SEIZURE; TOXIC EPIDERMAL NECROLYSIS; TREMOR; TUBEROUS SCLEROSIS; UROLITHIASIS; VISUAL FIELD DEFECT; WEIGHT GAIN; WEIGHT REDUCTION;

AMINES; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; CYCLOHEXANECARBOXYLIC ACIDS; EPILEPSY; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; PEDIATRICS; PHENYLCARBAMATES; PIRACETAM; PRACTICE GUIDELINES AS TOPIC; PROPYLENE GLYCOLS; TRIAZINES; VIGABATRIN;

EID: 49849105442     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2008.01.007     Document Type: Review

References (61)

1. Kwan P., and Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 6 (2006) 397-406
2. Pellock J.M., and Watemberg N. New antiepileptic drugs in children: present and future. Semin Pediatr Neurol 4 (1997) 9-18
3. Hadjiloizou S.M., and Bourgeois B.F. Antiepileptic drug treatment in children. Expert Rev Neurother 7 (2007) 179-193
4. Deckers C.L., Knoester P.D., de Haan G.J., Keyser A., Renier W.O., and Hekster Y.A. Selection criteria for the clinical use of the newer antiepileptic drugs. CNS Drugs 17 (2003) 405-421
5. Temple R.J., and Himmel M.H. Safety of newly approved drugs: implications for prescribing. JAMA 287 (2002) 2273-2275
6. Sankar R. Initial treatment of epilepsy with antiepileptic drugs: pediatric issues. Neurology 63 Suppl. 4 (2004) S30-S39
7. Crumrine P.K. Antiepileptic drug selection in pediatric epilepsy. J Child Neurol 17 (2002) 2S2-2S8
8. French J.A., Kanner A.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L., et al. Efficacy and tolerability of the new antiepileptic drugs, I: treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45 (2004) 401-409
9. French J.A., Kanner A.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L., et al. Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45 (2004) 410-423
10. Glauser T., Ben-Menachem E., Bourgeois B., Cnaan A., Chadwick D., Guerreiro C., et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47 (2006) 1094-1120
11. Wheless J.W., Clarke D.F., and Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 20 (2005) S1-S56
12. Bourgeois B.F. Felbamate. Semin Pediatr Neurol 4 (1997) 3-8
13. Rho J.M., Donevan S.D., and Rogawski M.A. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-d-aspartate and γ-aminobutyric acid A receptors. Ann Neurol 35 (1994) 229-234
14. Meldrum B. Action of established and novel anticonvulsant drugs on the basic mechanisms of epilepsy. Epilepsy Res Suppl 11 (1996) 67-77
15. Pellock J.M. Managing pediatric epilepsy syndromes with new antiepileptic drugs. Pediatrics 104 (1999) 1106-1116
16. Carmant L., Holmes G.L., Sawyer S., Rifai N., Anderson J., and Mikati M.A. Efficacy of felbamate in therapy for partial epilepsy in children. J Pediatr 125 (1994) 481-486
17. Hosain S., Nagarajan L., Carson D., Solomon G., Mast J., and Labar D. Felbamate for refractory infantile spasms. J Child Neurol 12 (1997) 466-468
18. Jarrar R.G., and Buchhalter J.R. Therapeutics in pediatric epilepsy, Part 1: the new antiepileptic drugs and the ketogenic diet. Mayo Clin Proc 78 (2003) 359-370
19. Graves N.M. Felbamate. Ann Pharmacother 27 (1993) 1073-1081
20. Kaufman D.W., Kelly J.P., Anderson T., Harmon D.C., and Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 38 (1997) 1265-1269
21. Pellock J.M., and Brodie M.J. Felbamate: 1997 update. Epilepsia 38 (1997) 1261-1264 [editorial]
22. Andrews C.O., and Fischer J.H. Gabapentin: a new agent for the management of epilepsy. Ann Pharmacother 28 (1994) 1188-1196
23. Trudeau V., Myers S., LaMoreaux L., Anhut H., Garofalo E., and Ebersole J. Gabapentin in naïve childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol 11 (1996) 470-475
24. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 42 (1996) 531-543
25. Wolf S.M., Shinnar S., Kang H., Gil K.B., and Moshe S.L. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 36 (1995) 1203-1205
26. Motte J., Trevathan E., Arvidsson J.F., Barrera M.N., Mullens E.L., and Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 337 (1997) 1807-1812
27. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 5 (1996) 149-151
28. Veggiotti P., Cieuta C., Rex E., and Dulac O. Lamotrigine in infantile spasms. Lancet 344 (1994) 1375-1376
29. Ferrie C.D., Robinson R.O., Knott C., and Panayiotopoulos C.P. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol Scand 91 (1995) 200-202
30. Uldall P., Hansen F.J., and Tonnby B. Lamotrigine in Rett syndrome. Neuropediatrics 24 (1993) 339-340
31. Culy C.R., and Goa K.L. Lamotrigine. A review of its use in childhood epilepsy. Pediatr Drugs 2 (2000) 299-330
32. Coppola G., Auricchio G., Federico R., Carotenuto M., and Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia 45 (2004) 1049-1053
33. Patsalos P.N. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia 46 Suppl. 9 (2005) 140-148
34. Klitgaard H., Matagne A., Gobert J., and Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353 (1998) 191-206
35. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., and Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 34 (1999) 1-41
36. Glauser T.A., Pellock J.M., Bebin E.M., Fountain N.B., Ritter F.J., Jensen C.M., et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43 (2002) 518-524
37. Krauss G.L., Betts T., Abou-Khalil B., Gergey G., Yarrow H., and Miller A. Levetiracetam treatment of idiopathic generalized epilepsy. Seizure 12 (2003) 617-620
38. Pellock J.M., Glauser T.A., Bebin E.M., Fountain N.B., Ritter F.J., Coupez R.M., et al. Pharmacokinetic study of levetiracetam in children. Epilepsia 42 (2001) 1574-1579
39. Vigevano F. Levetiracetam in pediatrics. J Child Neurol 20 (2005) 87-93
40. Tecoma E.S. Oxcarbazepine. Epilepsia 40 Suppl. 5 (1999) S37-S46
41. Bill P.A., Vigonius U., Pohlmann H., Guerreiro C.A., Kochen S., Saffer D., et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 27 (1997) 195-204
42. Christe W., Kramer G., Vigonius U., Pohlmann H., Steinhoff B.J., Brodie M.J., et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 26 (1997) 451-460
43. Glauser T.A. Expanding first-line therapy options for children with partial seizures. Neurology 55 Suppl. 3 (2000) S30-S37
44. Glauser T.A. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 21 (2001) 904-919
45. Glauser T.A. Preliminary observations on topiramate in pediatric epilepsies. Epilepsia 38 Suppl. 1 (1997) S37-S41
46. Glauser T.A., Clark P.O., and Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 39 (1998) 1324-1328
47. Biton V., Bourgeois B.F., and YTC/YTCE Study Investigators. Topiramate in patients with juvenile myoclonic epilepsy. Arch Neurol 62 (2005) 1705-1708
48. Elterman R.D., Glauser T.A., Wyllie E., Reife R., Wu S.C., Pledger G., et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 52 (1999) 1338-1344
49. Philippi H., Boor R., and Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 43 (2002) 744-747
50. Grant S.M., and Heel R.C. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 41 (1991) 889-926
51. Dulac O., Chiron C., Luna D., Cusmai R., Pajot N., Beaumont D., et al. Vigabatrin in childhood epilepsy. J Child Neurol Suppl. 2 (1991) S30-S37
52. Uldall P., Alving J., Gram L., and Hogenhaven H. Vigabatrin in childhood epilepsy: a 5-year follow-up study. Neuropediatrics 26 (1995) 253-256
53. Chiron C., Dulac O., Beaumont D., Palacios L., Pajot N., and Mumford J. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol Suppl. 2 (1991) S52-S59
54. Buncic J.R., Westall C.A., Panton C.M., Munn J.R., MacKeen L.D., and Logan W.J. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 111 (2004) 1935-1942
55. Miller N.R. Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants. Neurology 55 (2000) 333-334
56. Suzuki S., Kawakami K., Nishimura S., Watanabe Y., Yagi K., Seino M., et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 12 (1992) 21-27
57. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 20 (1998) 593-597
58. Seino M., Miyazaki H., and Ito T. Zonisamide. Epilepsy Res Suppl 3 (1991) 169-174
59. Glauser T.A., and Pellock J.M. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neurol 17 (2002) 87-96
60. Okumura A., Ishihara N., Kato T., Hayakawa F., Kuno K., and Watanabe K. Predictive value of acetylcholine stimulation testing for oligohydrosis caused by zonisamide. Pediatr Neurol 23 (2000) 59-61
61. Garofalo E. Clinical development of antiepileptic drugs for children. Neurotherapeutics 4 (2007) 70-74